WO2003105767A3 - Antifungal parenteral products - Google Patents

Antifungal parenteral products Download PDF

Info

Publication number
WO2003105767A3
WO2003105767A3 PCT/US2003/018754 US0318754W WO03105767A3 WO 2003105767 A3 WO2003105767 A3 WO 2003105767A3 US 0318754 W US0318754 W US 0318754W WO 03105767 A3 WO03105767 A3 WO 03105767A3
Authority
WO
WIPO (PCT)
Prior art keywords
antifungal
parenteral pharmaceutical
parenteral products
pharmaceutical formulations
antifungal compound
Prior art date
Application number
PCT/US2003/018754
Other languages
French (fr)
Other versions
WO2003105767A8 (en
WO2003105767A2 (en
Inventor
Martin Stogniew
Original Assignee
Vicuron Pharm Inc
Martin Stogniew
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicuron Pharm Inc, Martin Stogniew filed Critical Vicuron Pharm Inc
Priority to JP2004512675A priority Critical patent/JP4972750B2/en
Priority to AU2003248692A priority patent/AU2003248692B2/en
Priority to KR1020047020282A priority patent/KR100800503B1/en
Priority to EP03760347A priority patent/EP1511378A2/en
Priority to CA002488872A priority patent/CA2488872A1/en
Publication of WO2003105767A2 publication Critical patent/WO2003105767A2/en
Publication of WO2003105767A3 publication Critical patent/WO2003105767A3/en
Priority to IL16572004A priority patent/IL165720A0/en
Priority to NO20051648A priority patent/NO20051648L/en
Publication of WO2003105767A8 publication Critical patent/WO2003105767A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Abstract

Parenteral pharmaceutical formulations containing an echinocandin antifungal compound and an aqueous solvent are provided, wherein the formulation includes ethanol, for example about 20% w/v ethanol. The parenteral pharmaceutical formulation may further include one or more additives,such as a stabilizing agent, buffer or t onicity agent. The parenteral pharmaceutical formulations are useful in extending the shelf life and improving the solubility of the echinocandin antifungal compound.
PCT/US2003/018754 2002-06-13 2003-06-12 Antifungal parenteral products WO2003105767A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2004512675A JP4972750B2 (en) 2002-06-13 2003-06-12 Parenteral antifungal products
AU2003248692A AU2003248692B2 (en) 2002-06-13 2003-06-12 Antifungal parenteral products
KR1020047020282A KR100800503B1 (en) 2002-06-13 2003-06-12 Antifungal parenteral products
EP03760347A EP1511378A2 (en) 2002-06-13 2003-06-12 Antifungal parenteral products
CA002488872A CA2488872A1 (en) 2002-06-13 2003-06-12 Antifungal parenteral products
IL16572004A IL165720A0 (en) 2002-06-13 2004-12-12 Antifungal parenteral products
NO20051648A NO20051648L (en) 2002-06-13 2005-04-04 Antifungal parenteral products

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/172,678 US6991800B2 (en) 2002-06-13 2002-06-13 Antifungal parenteral products
US10/172,678 2002-06-13

Publications (3)

Publication Number Publication Date
WO2003105767A2 WO2003105767A2 (en) 2003-12-24
WO2003105767A3 true WO2003105767A3 (en) 2004-04-01
WO2003105767A8 WO2003105767A8 (en) 2005-05-19

Family

ID=29733139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018754 WO2003105767A2 (en) 2002-06-13 2003-06-12 Antifungal parenteral products

Country Status (11)

Country Link
US (2) US6991800B2 (en)
EP (1) EP1511378A2 (en)
JP (1) JP4972750B2 (en)
KR (1) KR100800503B1 (en)
AR (1) AR040226A1 (en)
AU (1) AU2003248692B2 (en)
CA (1) CA2488872A1 (en)
IL (1) IL165720A0 (en)
NO (1) NO20051648L (en)
TW (1) TW200400831A (en)
WO (1) WO2003105767A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022033B2 (en) 1999-03-03 2011-09-20 Eli Lilly And Company Echinocandin/carbohydrate complexes

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
DE60019902D1 (en) * 1999-03-03 2005-06-09 Lilly Co Eli ECHINOCANDIN PHARMACEUTICAL COMPOSITIONS
US6991800B2 (en) * 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
JP2008536856A (en) * 2005-04-13 2008-09-11 エラン・ファルマ・インターナショナル・リミテッド Nanoparticulate and sustained release composition comprising a prostaglandin derivative
WO2009048544A1 (en) * 2007-10-10 2009-04-16 Merck & Co., Inc. Liquid pharmaceutical compositions for parenteral administration of a substituted amide
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
JP2013503179A (en) * 2009-08-27 2013-01-31 シーチェイド ファーマシューティカルズ，インコーポレーテッド Echinocandine derivative
HUE036778T2 (en) 2011-03-03 2018-07-30 Cidara Therapeutics Inc Antifungal agents and uses thereof
AU2012250050B2 (en) 2011-04-28 2017-04-06 Platform Brightworks Two, Ltd. Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
ES2957620T3 (en) * 2012-03-19 2024-01-23 Cidara Therapeutics Inc Dosing Regimens for Echinocandin Class Compounds
RU2719579C2 (en) * 2013-03-14 2020-04-21 Сидара Терапьютикс, Инк. Dosing regimens for echinocandin class compounds
EA201791100A1 (en) * 2014-11-19 2017-11-30 Гуфик Байосайенсиз Лимитед METHOD OF OBTAINING A PARENTAL COMPOSITION BASED ON ANIDULAFUNGIN
CN105641678A (en) * 2014-12-03 2016-06-08 博瑞生物医药（苏州）股份有限公司 Anidulafungin parenteral preparation and preparation method thereof
ES2694561T3 (en) * 2015-02-23 2018-12-21 Selectchemie Ag Composition of anidulafungin
WO2017047299A1 (en) * 2015-09-15 2017-03-23 富士フイルム株式会社 Liquid composition for injection
EP3399995A4 (en) 2016-01-08 2019-08-21 Cidara Therapeutics, Inc. Methods for preventing and treating pneumocystis infections
US11712459B2 (en) 2016-03-16 2023-08-01 Cidara Therapeutics, Inc. Dosing regimens for treatment of fungal infections
CN106729723A (en) * 2016-11-21 2017-05-31 青岛农业大学 A kind of pharmaceutical composition containing UD-CG115BS.acardi and preparation method thereof
WO2018112330A1 (en) * 2016-12-16 2018-06-21 Baxter International Inc. Micafungin compositions
EP3651801A4 (en) 2017-07-12 2021-04-07 Cidara Therapeutics, Inc. Compositions and methods for the treatment of fungal infections
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
CN109481665B (en) * 2018-12-05 2019-08-06 广州迈达康医药科技有限公司 A kind of injection anidulafungin redissolves medicament and preparation method thereof
CA3132923A1 (en) * 2019-03-08 2020-09-17 Emphascience, Inc. Stable pharmaceutical formulations of peptide and protein drugs
MX2022006085A (en) * 2019-11-22 2023-03-01 Leiutis Pharmaceuticals Llp Stable parenteral formulations of duloxetine.
KR102162727B1 (en) 2020-04-22 2020-10-07 주식회사 이뮤니스바이오 Novel cell therapeutics composition by simultaneous administration of human cell-derived extracellular vesicles and cells
CN114015758B (en) * 2021-10-15 2022-06-24 无锡百泰克生物技术有限公司 Freeze-drying protective agent, fluorescent PCR detection kit and freeze-drying process

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030039667A1 (en) * 2001-08-27 2003-02-27 Vic Jira Anti-fungal composition
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
US160942A (en) * 1875-03-16 Improvement in farm-boxes
US161176A (en) * 1875-03-23 Improvement in heaters for cheese-vats
US151474A (en) * 1874-06-02 Improvement in corn-shellers
US2002A (en) * 1841-03-12 Tor and planter for plowing
US54981A (en) * 1866-05-22 Improvement in nail-machines
US3293482A (en) * 1962-06-21 1966-12-20 Rca Corp Plural output traveling wave tube
JPS5134916B2 (en) * 1974-03-06 1976-09-29
DE2803581A1 (en) 1978-01-27 1979-08-02 Sandoz Ag Antifungal antibiotic tetra-hydro-echinocandin-b ether derivs. - prepd. e.g. by condensation of tetra-hydro-echinocandin B with amino-alcohol cpds.
US4293489A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
CA1183127A (en) 1979-12-13 1985-02-26 Manuel Debono Process for the preparation of derivatives of cyclic peptide nuclei
US4293482A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company A-30912A Nucleus
US4293483A (en) * 1979-12-13 1981-10-06 Eli Lilly And Company Derivatives of A-30912A nucleus
US4299763A (en) * 1979-12-13 1981-11-10 Eli Lilly And Company A-30912B Nucleus
US4320052A (en) * 1979-12-13 1982-03-16 Eli Lilly And Company Derivatives of A-30912A nucleus
US4304716A (en) * 1979-12-13 1981-12-08 Eli Lilly And Company S 31794/F-1 Nucleus
CA1170598A (en) 1979-12-13 1984-07-10 Bernard J. Abbott Process for the preparation of cyclic peptide nuclei
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
US5141674A (en) * 1984-03-08 1992-08-25 Phares Pharmaceutical Research N.V. Methods of preparing pro-liposome dispersions and aerosols
US4876241A (en) * 1987-05-22 1989-10-24 Armour Pharmaceutical Company Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
DK173802B1 (en) 1988-09-12 2001-11-05 Merck & Co Inc Preparation for the treatment of Pneumocystis carinii infections and use of a cyclohexapeptide for the preparation of a drug against Pneumocystis carinii infections
AU617541B2 (en) 1988-10-20 1991-11-28 Wyeth Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US4927831A (en) * 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
US5202309A (en) * 1989-06-30 1993-04-13 Merck & Co., Inc. Antibiotic cyclopeptide fermentation product
JPH03240727A (en) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd Remedy for pneumocystosis-carinii pneumonia
CA2037957A1 (en) 1990-03-12 1991-09-13 Merck & Co., Inc. N-acylated cyclohexapeptide compounds
GB2241956A (en) 1990-03-16 1991-09-18 Merck & Co Inc N-acylated cyclohexapeptide compounds
IL97347A0 (en) 1990-03-19 1992-05-25 Merck & Co Inc Lipopeptide derivatives and antimicrobial compositions containing them
US5386009A (en) 1990-03-19 1995-01-31 Merck & Co. Inc. Lipopeptide derivatives
US5049546A (en) 1990-03-19 1991-09-17 Merck & Co., Inc. Antibiotic agents
US5330973A (en) 1990-03-19 1994-07-19 Merck & Co., Inc. Lipopeptide derivatives
US5310726A (en) 1990-03-19 1994-05-10 Merck & Co., Inc. Lipopeptide compounds
IE910892A1 (en) 1990-03-19 1991-09-25 Merck & Co Inc Lipopeptide compounds
EP0460882B1 (en) * 1990-06-07 1996-07-24 Eli Lilly And Company Lipopeptide deacylase
IE912046A1 (en) * 1990-06-18 1991-12-18 Fujisawa Pharmaceutical Co New polypeptide compound and a process for preparation¹thereof
US5198421A (en) * 1991-04-26 1993-03-30 Merck & Co., Inc. Phosphorylated cyclic lipopeptide
EP0486011A3 (en) 1990-11-16 1992-07-15 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical composition against pneumocystis carinii
US5369093A (en) 1991-03-15 1994-11-29 Merck & Co., Inc. Lipopeptide derivatives
US5993805A (en) * 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5233023A (en) 1991-07-30 1993-08-03 Merck & Co., Inc. Process for phosphate ester compounds of certain cyclohexapeptides
JPH05271097A (en) 1991-10-07 1993-10-19 Asahi Chem Ind Co Ltd Aculeacin solubilizing agent and medicinal composition
US6743777B1 (en) * 1992-03-19 2004-06-01 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US6384013B1 (en) * 1992-03-19 2002-05-07 Eli Lilly And Company Cyclic peptide antifungal agents and process for preparation thereof
US5965525A (en) * 1992-03-19 1999-10-12 Eli Lilly And Company Cyclic peptide antifungal agents
CZ288974B6 (en) 1992-03-19 2001-10-17 Eli Lilly And Company Acyl derivative of echinocandine, process of its preparation, pharmaceutical preparation in which the derivative is comprised and use thereof
DE69232220D1 (en) 1992-09-22 2002-01-03 Takeo Takayanagi Carbohydrate complexes for the destruction of cancer cells
JPH06172205A (en) 1992-12-11 1994-06-21 Asahi Chem Ind Co Ltd Fat emulsifier containing acreasin compounds
US5383324A (en) 1993-04-23 1995-01-24 Baxter International Inc. Method for manufacturing and storing stable bicarbonate solutions
JPH09500103A (en) * 1993-05-04 1997-01-07 メルク エンド カンパニー インコーポレーテッド Cyclohexapeptidyl aminoalkyl ether
IS1796B (en) * 1993-06-24 2001-12-31 Ab Astra Inhaled polypeptide formulation composition which also contains an enhancer compound
US5541160A (en) * 1994-04-04 1996-07-30 Merck & Co., Inc. Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5646111A (en) * 1995-04-07 1997-07-08 Eli Lilly And Company Cyclic peptide antifungal Agents
US5618787A (en) * 1995-05-26 1997-04-08 Eli Lilly And Company Cyclic peptide antifungal agents
US5652213A (en) 1995-05-26 1997-07-29 Eli Lilly And Company Cyclic peptide antifungal agents
US5786325A (en) * 1995-05-26 1998-07-28 Eli Lilly And Company Cyclic peptide antifungal agents and methods of making and using
US5629290A (en) * 1995-05-26 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US5629289A (en) 1995-07-25 1997-05-13 Eli Lilly And Company Cyclic peptide antifungal agents
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
FR2740686B1 (en) * 1995-11-03 1998-01-16 Sanofi Sa STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION
US5693611A (en) * 1996-02-01 1997-12-02 Eli Lilly And Company Cyclic peptide antifungal agents
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
EP0971698A4 (en) * 1996-12-31 2006-07-26 Nektar Therapeutics Aerosolized hydrophobic drug
AU8687798A (en) * 1997-08-04 1999-02-22 Eli Lilly And Company Cyclic peptide antifungal agents
US5972996A (en) * 1997-08-22 1999-10-26 Merck & Co., Inc. 4-cyano-4-deformylsordarin derivatives
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
CA2255140A1 (en) 1997-12-23 1999-06-23 Eli Lilly And Company Echinocandin binding domain of 1,3-.beta.-glucan synthase
DE19800287A1 (en) * 1998-01-07 1999-07-08 Bayer Ag Aliphatic sinterable thermoplastic polyurethane molding compounds with reduced mechanical strength
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
US6284282B1 (en) * 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US6423345B2 (en) * 1998-04-30 2002-07-23 Acusphere, Inc. Matrices formed of polymer and hydrophobic compounds for use in drug delivery
US6451349B1 (en) * 1998-08-19 2002-09-17 Quadrant Healthcare (Uk) Limited Spray-drying process for the preparation of microparticles
ES2233070T3 (en) * 1998-08-20 2005-06-01 ELI LILLY & COMPANY SYNTHESIS OF CYCLED PEPTIDIC ANALOGS MODIFIED IN THE RING.
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000034315A2 (en) * 1998-12-09 2000-06-15 Eli Lilly And Company Purification of echinocandin cyclopeptide compounds
JP4063497B2 (en) * 1999-03-03 2008-03-19 イーライ リリー アンド カンパニー Formation and anion exchange of echinocandin ammonium salt crystals
KR20020003864A (en) 1999-03-03 2002-01-15 피터 지. 스트링거 Echinocandin/carbohydrate complexes
EP1156784A1 (en) 1999-03-03 2001-11-28 Eli Lilly And Company Processes for making pharmaceutical oral ecb formulations and compositions
DE60019902D1 (en) 1999-03-03 2005-06-09 Lilly Co Eli ECHINOCANDIN PHARMACEUTICAL COMPOSITIONS
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US20030039667A1 (en) * 2001-08-27 2003-02-27 Vic Jira Anti-fungal composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GROLL A. ET AL.: "Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 45, no. 10, October 2001 (2001-10-01), pages 2845 - 2855, XP002972087 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022033B2 (en) 1999-03-03 2011-09-20 Eli Lilly And Company Echinocandin/carbohydrate complexes

Also Published As

Publication number Publication date
CA2488872A1 (en) 2003-12-24
JP4972750B2 (en) 2012-07-11
US20040223997A1 (en) 2004-11-11
US6991800B2 (en) 2006-01-31
AU2003248692B2 (en) 2008-07-31
NO20051648L (en) 2005-04-04
AU2003248692A1 (en) 2003-12-31
KR100800503B1 (en) 2008-02-04
TW200400831A (en) 2004-01-16
AR040226A1 (en) 2005-03-16
US20050261173A1 (en) 2005-11-24
JP2005533056A (en) 2005-11-04
IL165720A0 (en) 2006-01-15
US7198796B2 (en) 2007-04-03
WO2003105767A8 (en) 2005-05-19
EP1511378A2 (en) 2005-03-09
WO2003105767A2 (en) 2003-12-24
KR20050016552A (en) 2005-02-21

Similar Documents

Publication Publication Date Title
WO2003105767A8 (en) Antifungal parenteral products
MXPA03007942A (en) Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability.
EP1472230A4 (en) Ansamycins having improved pharmacological and biological properties
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
RS105704A (en) Acidic insulin preparations with improved stability
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
CY1113391T1 (en) USE OF A COMPONENT SOLUBLE STRENGTHENING IN AQUATIC COMPOSITION CONTAINING TRAGIC BRIMONIDIN
GEP20094627B (en) High drug load tablet
MXPA06002668A (en) NONSEDATING Alpha-2 AGONIST 1- (2, 3-DIMETHYL-PHENYL) -ETHYL-1, 3-DIHYDRO-IMIZADOLE-2-THIONE.
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
EP2269608A3 (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
EA200101275A1 (en) COMPOSITIONS CONTAINING CREATIN IN SUSPENSION
BG106046A (en) Pharmaceutical compositions of ertythropoietin
WO2004037289A3 (en) Novel injectable depot formulations
WO2001032652A3 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
CY1107142T1 (en) STANDARDIZATION INCLUDING FULVESTRANT
WO2004014388A8 (en) 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
AU2002239348A1 (en) Pyrazolopyridine derivatives
TW200517106A (en) Sustained release pharmaceutical compositions
CA2366679A1 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
TW200502231A (en) Prodrugs of proton pump inhibitors
SI1407763T1 (en) Compositions containing a cosmetically active organic acid and a legume product
TW200420557A (en) Salt of 7-isoindoline-quinolonecarboxylic acid derivative, its hydrate and anti-bacterially pharmaceutical composition comprising the same as active ingredient
EP1284272A4 (en) Estra-1,3,5(10)-triene derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2488872

Country of ref document: CA

Ref document number: 2004512675

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020047020282

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003248692

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003760347

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047020282

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003760347

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 52/2003 UNDER (84) ADD "EP (EE, SK)"